You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 751 Monotherapy results from an ongoing phase 1a dose escalation study of NDI-101150, a highly selective oral hematopoietic progenitor kinase 1 (HPK1) inhibitor

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
751 Monotherapy results from an ongoing phase 1a dose escalation study of NDI-101150, a highly selective oral hematopoietic progenitor kinase 1 (HPK1) inhibitor

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023412042
Dec 2023180032
Jan 2024101018
Feb 202492010
Mar 202496029
Apr 202462012
May 202458013
Jun 2024104012
Jul 2024138013
Aug 202470013
Sep 202462018
Oct 2024126027
Nov 2024108020
Dec 20244803
Jan 202580016
Feb 20252609
Mar 20250013
Apr 2025104
May 20250012
Jun 2025007
Total17640323